All In Biotech

Drug Trial Radar · NCT00880308

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

103

Actual

Start

Mar 2009

Primary completion

Jul 2013

Study completion Jul 2013

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 13, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor Cancers
  • Medulloblastoma
  • Basal Cell Carcinoma

Interventions

  • LDE225Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. determine maximum tolerated dose of single agent LDE225Time frame: 28 day cycles

Locations

5 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Pittsburgh Medical Center SC

    Pittsburgh, Pennsylvania

  • Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5)

    San Antonio, Texas

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Zurich, Switzerland

  • Novartis Investigative Site

    Leicester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.